EFFECTOR Therapeutics, Inc. (EFTRW)의 가격은 얼마입니까?

EFFECTOR Therapeutics, Inc. (EFTRW)의 가격은 $0.0006입니다.

EFFECTOR Therapeutics, Inc. (EFTRW)의 시가 총액은 무엇입니까?

EFFECTOR Therapeutics, Inc. (EFTRW)의 시가 총액은 $2.82K입니다.

EFFECTOR Therapeutics, Inc. (EFTRW) 액면분할

eFFECTOR Therapeutics, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective translation regulator inhibitors aimed at combating cancer. Their primary investigational drug, Tomivosertib, is an orally administered small-molecule MNK inhibitor currently undergoing Phase 2b clinical trials. This candidate is being evaluated for its efficacy in patients suffering from metastatic non-small cell lung cancer. Additionally, the company is advancing zotatifin, another small molecule engineered to block eukaryotic initiation factor 4A (eIF4E). Zotatifin is presently in Phase 1/2 clinical studies for individuals with various solid tumors. Furthermore, it's being tested in a Phase 2a open-label expansion cohort, in conjunction with fulvestrant and abemaciclib, for patients afflicted with ER-positive breast cancer. eFFECTOR Therapeutics, Inc. also holds a research collaboration and licensing pact with Pfizer Inc., focused on co-developing eIF4E inhibitors. Established in 2012, the company maintains its corporate headquarters in Solana Beach, California.

연도	주식 분할	배수	누적 배수
제공된 날짜에 대한 데이터가 충분하지 않습니다.

연도

주식 분할

배수

누적 배수

제공된 날짜에 대한 데이터가 충분하지 않습니다.

회사	주식 분할 횟수	누적 배수	국가
Vertex Pharmaceuticals Incorporated VRTX.US	1	x2	US
Argenx SE ARGX.US	0	-	NL
Lonza Group AG LONN.SW	0	-	CH
UCB S.A. UCB.BR	0	-	BE
Samsung Biologics Co.,Ltd. 207940.KS	0	-	KR

회사

주식 분할 횟수

누적 배수

국가